Ameris Bancorp delivered a second quarter that, on a reported basis, looks like a franchise reset: GAAP net income of $51.4 million, or $0.77 per diluted share, was less than half the $109.8 million, or $1.60, earned a year earlier, with the gap entirely attributable to an $82.5 million pre-tax litigation accrual tied to a California employment-jury verdict that the company is appealing. Strip out the one-time charge and the gain on a Visa share conversion, and the operating story is intact: adjusted net income of $107.3 million, or $1.60 per diluted share, came in flat to the prior year, the net interest margin held at 3.88% on a tax-equivalent basis, annualized loan growth of 6.4% continued, and the efficiency ratio on the adjusted basis actually tightened to 50.42% from 51.74% a year ago.
The Q2 print leaves us with three concurrent narratives the market is repricing in real time. First, the litigation overhang: the $82.5 million accrual is sized to the jury's $16.525 million in economic and non-economic damages plus roughly $62.9 million in punitive damages, and the appeal process is the next twelve-to-eighteen-month clock the equity is being priced against. Second, the margin-defense story: NIM held flat at 3.88% on a 3-basis-point increase in cost of funds, with 30.0% noninterest-bearing deposit mix acting as the buffer, and a 4-basis-point expansion in earning-asset yield to 5.61% reflecting a 40-basis-point lift in taxable-securities yield as the portfolio reprices into the front end. Third, capital deployment: $19.0 million of Q2 buybacks and a $0.20 quarterly dividend returned $32.4 million, with $65.4 million of capacity remaining under the $200.0 million October 2025 authorization through October 31, 2026.
The question the quarter forces: at a $6.02 billion market cap, the equity is trading at 1.99x tangible book value, 16.2x trailing GAAP earnings, and 14.2x trailing adjusted earnings - pricing the litigation as a one-time non-recurring event, the NIM defense as durable through the second-half rate path, and the Nashville de novo expansion as a low-cost additive to the Southeast franchise rather than a value-destructive acquisition. The falsifiable clock is the Q3 2026 print in late October: if adjusted ROTCE re-accelerates above 14.5% and the litigation reserve is held or released on appeal, the market clears the litigation overhang and the P/TBV multiple compresses through 1.85x as the buyback window fills; if adjusted ROTCE drops below 13.5% on provision normalization and a 5-basis-point NIM compression, the multiple defensively retests the 1.70x 52-week-low band.